273 related articles for article (PubMed ID: 22003219)
1. Activation of the hemostatic system during cardiopulmonary bypass.
Sniecinski RM; Chandler WL
Anesth Analg; 2011 Dec; 113(6):1319-33. PubMed ID: 22003219
[TBL] [Abstract][Full Text] [Related]
2. Strategies to reduce hemostatic activation during cardiopulmonary bypass.
Eisses MJ; Velan T; Aldea GS; Chandler WL
Thromb Res; 2006; 117(6):689-703. PubMed ID: 15996721
[TBL] [Abstract][Full Text] [Related]
3. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass.
Tabuchi N; de Haan J; Boonstra PW; van Oeveren W
J Thorac Cardiovasc Surg; 1993 Nov; 106(5):828-33. PubMed ID: 8231204
[TBL] [Abstract][Full Text] [Related]
4. Reducing hemostatic activation during cardiopulmonary bypass: a combined approach.
Eisses MJ; Seidel K; Aldea GS; Chandler WL
Anesth Analg; 2004 May; 98(5):1208-16, table of contents. PubMed ID: 15105189
[TBL] [Abstract][Full Text] [Related]
5. The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery.
Kuitunen A; Hiippala S; Vahtera E; Rasi V; Salmenperä M
Acta Anaesthesiol Scand; 2005 Oct; 49(9):1272-9. PubMed ID: 16146463
[TBL] [Abstract][Full Text] [Related]
6. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
Despotis GJ; Joist JH
J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
[TBL] [Abstract][Full Text] [Related]
7. Cardiopulmonary bypass parameters and hemostatic response to cardiopulmonary bypass in infants versus children.
Eisses MJ; Chandler WL
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):53-9. PubMed ID: 18249331
[TBL] [Abstract][Full Text] [Related]
8. The impact of cardiac ischemia and reperfusion on markers of activated haemostasis and fibrinolysis during cardiopulmonary bypass: comparison of plasma levels in arterial and coronary venous blood.
Kalweit G; Bach J; Huwer H; Winning J; Hellstern P
Thromb Res; 2005; 116(1):33-9. PubMed ID: 15850606
[TBL] [Abstract][Full Text] [Related]
9. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management.
Koster A; Fischer T; Praus M; Haberzettl H; Kuebler WM; Hetzer R; Kuppe H
Anesthesiology; 2002 Oct; 97(4):837-41. PubMed ID: 12357148
[TBL] [Abstract][Full Text] [Related]
10. Effects of hemodilution, blood loss, and consumption on hemostatic factor levels during cardiopulmonary bypass.
Chandler WL
J Cardiothorac Vasc Anesth; 2005 Aug; 19(4):459-67. PubMed ID: 16085250
[TBL] [Abstract][Full Text] [Related]
11. Management of heparin resistance during cardiopulmonary bypass: the effect of five different anticoagulation strategies on hemostatic activation.
Koster A; Fischer T; Gruendel M; Mappes A; Kuebler WM; Bauer M; Kuppe H
J Cardiothorac Vasc Anesth; 2003 Apr; 17(2):171-5. PubMed ID: 12698397
[TBL] [Abstract][Full Text] [Related]
12. Effect of polymer coating (poly 2-methoxyethylacrylate) of the oxygenator on hemostatic markers during cardiopulmonary bypass in children.
Eisses MJ; Geiduschek JM; Jonmarker C; Cohen GA; Chandler WL
J Cardiothorac Vasc Anesth; 2007 Feb; 21(1):28-34. PubMed ID: 17289476
[TBL] [Abstract][Full Text] [Related]
13. Closed cardiopulmonary bypass circuits suppress thrombin generation during coronary artery bypass grafting.
Nakahira A; Sasaki Y; Hirai H; Fukui T; Matsuo M; Takahashi Y; Kotani S; Suehiro S
Interact Cardiovasc Thorac Surg; 2010 Apr; 10(4):555-60. PubMed ID: 20061337
[TBL] [Abstract][Full Text] [Related]
14. Changes in hemostasis during pediatric heart surgery: impact of a biocompatible heparin-coated perfusion system.
Jensen E; Andréasson S; Bengtsson A; Berggren H; Ekroth R; Larsson LE; Ouchterlony J
Ann Thorac Surg; 2004 Mar; 77(3):962-7. PubMed ID: 14992907
[TBL] [Abstract][Full Text] [Related]
15. Early activation of hemostasis during cardiopulmonary bypass: evidence for thrombin mediated hyperfibrinolysis.
Teufelsbauer H; Proidl S; Havel M; Vukovich T
Thromb Haemost; 1992 Sep; 68(3):250-2. PubMed ID: 1440486
[TBL] [Abstract][Full Text] [Related]
16. Thrombin receptor-related hemostatic defect after cardiopulmonary bypass.
Ferraris VA; Ferraris SP; Reich H; Rodriguez E; Huang M; Gupta A; Bennett JA; Andersen TT; Fenton JW
Semin Thromb Hemost; 1996; 22(4):351-6. PubMed ID: 8944421
[TBL] [Abstract][Full Text] [Related]
17. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
18. Hemostasis during normal pregnancy and puerperium.
Hellgren M
Semin Thromb Hemost; 2003 Apr; 29(2):125-30. PubMed ID: 12709915
[TBL] [Abstract][Full Text] [Related]
19. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin coated cardiopulmonary bypass equipment.
Nakajima T; Osawa S; Ogawa M; Sasaki T; Izumoto H; Yagi Y; Kawazoe K
ASAIO J; 1996; 42(4):301-5. PubMed ID: 8828788
[TBL] [Abstract][Full Text] [Related]
20. A biocompatible cardiopulmonary bypass strategy to reduce hemostatic and inflammatory alterations: a randomized controlled trial.
Paparella D; Scrascia G; Rotunno C; Marraudino N; Guida P; De Palo M; Rubino G; Cappabianca G
J Cardiothorac Vasc Anesth; 2012 Aug; 26(4):557-62. PubMed ID: 22658688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
